A phase II study of KOS-862 (Epothilone D) administered intravenously weekly for 3 weeks, in patients with metastatic breast cancer
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2006
At a glance
- Drugs Epothilone D (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 23 Jan 2006 New trial record.